GENE ONLINE|News &
Opinion
Blog

2021-01-20| COVID-19R&D

COVID-19: Another Study Suggests Pfizer/BioNTech Vaccine is Capable of Neutralizing UK Variant

by Rajaneesh K. Gopinath
Share To

January 20th, 2021 – According to a new study conducted by Pfizer and BioNTech, the rapidly spreading UK COVID variant is unlikely to escape from the neutralizing antibodies generated by the BNT162b2 vaccine. These encouraging findings provide additional data to support Pfizer’s in vitro study results released earlier this month.

 

B.1.1.7 Coronavirus Variant

The new fast-spreading coronavirus variant detected in the United Kingdom last September raised concerns among health officials. Scientists too rushed to ascertain whether the recently authorized COVID-19 vaccines can protect from it.

The SARS-CoV-2 lineage B.1.1.7 (VUI-202012/01) surprised several researchers since it harbored an “unusually large number of mutations” with as many as 10 amino acid changes in the spike (S) protein, which binds to the human ACE2 receptor for viral entry. The mutations are ΔH69/V70, ΔY144, N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H.

Among them, the N501Y mutation was alarming since it altered a key residue in the receptor-binding domain (RBD) of S protein. The would result in an increased affinity of S RBD towards ACE2, meaning there would be tight binding between the virus and the host cell. This mutation is also found in the variant identified in South Africa.

However, vaccine manufacturers expressed confidence that their vaccines can work against variants. Both Pfizer and BioNTech, who partnered to develop the BNT162b2 mRNA vaccine, strongly believed that this problem could be sorted, given B.1.1.7’s proteins are 99% the same as that of the original SARS-CoV-2 strain.

 

Encouraging Studies Supporting BNT16b2 Efficacy against Variants

On January 8th, Pfizer and BioNTech announced results from an in vitro study showing that the BNT162b2-immune sera derived from 20 vaccinated individuals neutralized SARS-CoV-2 that harbored an N501Y mutation as efficiently as the original Wuhan strain. The preliminary study results were published in the preprint server bioRXiv and are yet to be peer-reviewed.

However, it had to be investigated whether the immune sera could be effective against the full set of mutations present in the B.1.1.7 spike. To answer that, a study was performed with blood samples collected from 16 vaccinated individuals who participated in an earlier Phase 1/2 trial. Blood was drawn from the 16 individuals (eight from the 18-55 yrs age group and eight from the 56-85 yrs age group) at 21 days after they were administered with the second dose.

The immune sera isolated from the samples were exposed to engineered VSV-SARS-CoV-2-S pseudoviruses that either featured the unmutated SARS-CoV-2 spike or the B.1.1.7 spike harboring the 10 mutations. The 50% neutralization assay (pVNT50) showed no biologically significant difference in neutralization activity against the two pseudoviruses.

Keeping in mind the evolution of COVID-19 strains, the study stressed that further testing is required to monitor the efficacy of the vaccines against the continuous emergence of new variants. Nevertheless, the companies expressed that they are encouraged by these findings.

It would be interesting to see if these results could be replicated for the South African strain. However, BioNTech is confident that, even if a vaccine strain change is warranted, it is possible to make that adjustment quickly using its proprietary mRNA vaccine platform.

Related Article: Johnson & Johnson’s Single Dose COVID-19 Vaccine is Safe and Promising

References
  1. https://www.biorxiv.org/content/10.1101/2021.01.07.425740v1
  2. https://www.biorxiv.org/content/10.1101/2021.01.18.426984v1
  3. https://investors.biontech.de/news-releases/news-release-details/pfizer-and-biontech-publish-results-study-showing-covid-19
  4. https://www.pfizer.com/news/press-release/press-release-detail/vitro-study-shows-pfizer-biontech-covid-19-vaccine-elicits

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Pfizer To Invest $1.26 Billion In Irish Plant, Forms New Vant Company Targeting Inflammation
2022-12-02
CDC Warns Of “Tripledemic” Winter Amid Rising Flu And RSV Cases
2022-11-14
Sanofi, GSK Secure European COVID-19 Booster Approval, AstraZeneca Withdraws U.S. Application
2022-11-10
LATEST
Rebyota Passes Through FDA To Become First Approved Fecal Microbiota Product
2022-12-05
RemeGen Presented New Data Updates on Telitacicept for SLE and primary Sjogren’s syndrome at ACR Convergence 2022
2022-12-05
EMA Urges Pholcodine’s Removal from European Market Following Safety Study
2022-12-05
Lynk Pharmaceuticals Announces First Patient Dosed in Phase Ⅱ Clinical Study of LNK01003 in Patients with Ulcerative Colitis
2022-12-04
Cure Brain Cancer Foundation Rings Nasdaq Opening Bell, Announces U.S. Expansion
2022-12-02
Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Full-Life Technologies
2022-12-02
Pfizer To Invest $1.26 Billion In Irish Plant, Forms New Vant Company Targeting Inflammation
2022-12-02
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2022-12-21
Avatar Medicine Forum
Online
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!